• Efficacy and Safety of Besifovir Dipivoxil Maleate in a Phase 3 Trial of Patients With Chronic HBV Infection

Efficacy and Safety of Besifovir Dipivoxil Maleate in a Phase 3 Trial of Patients With Chronic HBV Infection

The efficacy of 48 weeks treatment with besifovir dipivoxil maleate (BSV) for chronic hepatitis B virus (HBV) infection is comparable to that of tenofovir disoproxil fumarate (TDF), with durable effects for 96 weeks, researchers report in the August issue of Clinical Gastroenterology and Hepatology. BSV has a better safety profile

Read more
  • Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia and Chronic Liver Disease

Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia and Chronic Liver Disease

Lusutrombopag, an oral small molecule agonist of the thrombopoietin receptor, achieves and maintains target platelet count in patients with chronic liver disease and thrombocytopenia undergoing invasive procedures, researchers report in a phase 3, placebo-controlled trial published in the May issue of Clinical Gastroenterology and Hepatology. The drug caused no significant

Read more
  • What is the Best Treatment Option for Fistulizing Crohn’s Disease?

What is the Best Treatment Option for Fistulizing Crohn’s Disease?

Tumor necrosis factor (TNF) antagonists are effective for induction and maintenance of perianal fistula response and remission in patients with Crohn’s disease (CD), a systematic review and meta-analysis shows in the December issue of Clinical Gastoenterology and Hepatology. However, there are few data on the effects on internal fistulae, and further studies

Read more
  • What Are the Best Endpoints for Trials of Agents for Ulcerative Colitis?

What Are the Best Endpoints for Trials of Agents for Ulcerative Colitis?

Despite advances in methods of clinical trials for ulcerative colitis (UC), there is still a large amount of variation in endpoints, even in definitions of response and remission, reseachers found in a systematic review published in the May issue of Clinical Gastroenterology and Hepatology. The authors conclude that we need a

Read more
  • Does Immunomodulator Therapy for IBD During Pregnancy Affect Newborn Response to Vaccines?

Does Immunomodulator Therapy for IBD During Pregnancy Affect Newborn Response to Vaccines?

Rates of adequate serologic response to Haemophilus influenzae B (HiB) and tetanus vaccines are similar among infants born to women with inflammatory bowel diseases (IBD) treated with immunomodulator or biologic agents compared to women who did not receive these immunosuppressive drugs during pregnancy, researchers report in the January issue of Clinical Gastroenterology

Read more
  • Bioinformatic Search Identifies Tapeworm Drug for Treatment of Hepatocellular Carcinoma

Bioinformatic Search Identifies Tapeworm Drug for Treatment of Hepatocellular Carcinoma

In a bioinformatic search for agents that alter the hepatocellular carcinoma (HCC)-specific gene expression pattern, researchers identified the anthelmintic drug niclosamide as a potential anti-tumor agent, described in the June issue of Gastroenterology. Niclosamide and its ethanolamine salt (NEN), with greater bioavailability, slowed growth of genetically induced liver tumors and

Read more
  • A Mouse Model for Studying Pancreatic Tumor Resection and Adjuvant Therapy

A Mouse Model for Studying Pancreatic Tumor Resection and Adjuvant Therapy

Researchers have developed mice that develop focal, resectable pancreatic tumors closely resembling human pancreatic ductal adenocarcinomas (PDACs) that can be used to test adjuvant therapies, according to new research in the August issue of Gastroenterology. The authors show that administration of gemcitabine after resection of the tumors activates natural killer (NK) cell-mediated

Read more
  • Do Nonselective Beta Blockers Increase Mortality in Patients With Cirrhosis and Ascites?

Do Nonselective Beta Blockers Increase Mortality in Patients With Cirrhosis and Ascites?

Nonselective beta blockers (NSBBs) do not significantly increase the risk of death in patients with cirrhosis and ascites or refractory ascites, researchers report in the August issue of Clinical Gastroenterology and Hepatology. The findings from this meta-analysis do not support the position that NSBBs be routinely withheld from patients with

Read more

What Happens to Infants Whose Mothers Took Anti-TNF Agents During Pregnancy?

Anti-tumor necrosis factor (TNF) agents can be detected in infants born to mothers with inflammatory bowel diseases (IBD) who took the drugs during pregnancy, researchers report in the July issue of Gastroenterology. Infliximab is cleared more slowly than adalimumab from infants. However, measureable levels in infants do not seem to be

Read more
  • Long-term Efficacy of Octreotide in Patients with Polycystic Kidney and Liver Disease

Long-term Efficacy of Octreotide in Patients with Polycystic Kidney and Liver Disease

Three years of long-acting release octreotide (octreotide LAR) significantly reduced liver volume in patients with polycystic kidney and liver disease, researchers found in a placebo-controlled study. These reductions, reported in the July issue of Clinical Gastroenterology and Hepatology, were maintained for 2 years after treatment ended. Polycystic liver disease (PLD)

Read more